ClinVar Miner

Submissions for variant NM_006767.4(LZTR1):c.850C>T (p.Arg284Cys)

gnomAD frequency: 0.00001  dbSNP: rs797045165
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000658480 SCV000778847 pathogenic not provided 2021-11-12 criteria provided, single submitter clinical testing Published functional studies demonstrate the variant results in the upregulation of RAS-MAPK signaling (Motta et al., 2019); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30664951, 29346770, 25795793, 27942422, 26446362, 25335493, 30481304)
Fulgent Genetics, Fulgent Genetics RCV000763073 SCV000893583 pathogenic Schwannomatosis 2; Noonan syndrome 10 2018-10-31 criteria provided, single submitter clinical testing
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego RCV000191028 SCV000996259 pathogenic Noonan syndrome 10 2019-03-01 criteria provided, single submitter clinical testing This variant has been previously reported as a heterozygous change in six related individuals with autosomal dominant Noonan Syndrome (PMID: 25795793) and as an apparently de novo change in an individual with schwannomatosis (PMID: 25335493). It is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. This variant has been classified as a de novo pathogenic variant for Noonan syndrome in ClinVar (Variation ID: 209089). In-silico analyses support a damaging effect of the c.850C>T (p.Arg284Cys) variant on protein function. Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, the c.850C>T (p.Arg284Cys) variant is classified as pathogenic.
Invitae RCV000658480 SCV002141150 pathogenic not provided 2023-11-11 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 284 of the LZTR1 protein (p.Arg284Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Noonan syndrome and/or schwannomatosis (PMID: 25335493, 25795793, 30664951). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 209089). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt LZTR1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects LZTR1 function (PMID: 30481304). For these reasons, this variant has been classified as Pathogenic.
MGZ Medical Genetics Center RCV000191028 SCV002580990 pathogenic Noonan syndrome 10 2022-09-06 criteria provided, single submitter clinical testing
Ambry Genetics RCV002444774 SCV002681537 pathogenic Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2023-11-01 criteria provided, single submitter clinical testing The p.R284C pathogenic mutation (also known as c.850C>T), located in coding exon 9 of the LZTR1 gene, results from a C to T substitution at nucleotide position 850. The arginine at codon 284 is replaced by cysteine, an amino acid with highly dissimilar properties. In one large Brazilian family, this alteration arose de novo in an individual affected with Noonan syndrome and segregated with disease in an autosomal dominant manner in that patient's offspring (Yamamoto GL et al. J. Med. Genet., 2015 Jun;52:413-21). This mutation has been reported in the literature in other individuals with autosomal dominant Noonan syndrome (Jacquinet A Eur J Med Genet 2020 Jan;63(1):103617; Bertola DR et al. Am J Med Genet C Semin Med Genet 2020 12;184(4):896-911). This variant has also been reported in an individual with schwannomatosis (Paganini I et al. Eur. J. Hum. Genet., 2015 Jul;23:963-8). Functional studies indicate that this alteration enhances RAS-MAPK signaling (Motta M et al. Hum. Mol. Genet., 2019 03;28:1007-1022). Based on the supporting evidence, this variant is pathogenic for autosomal dominant Noonan syndrome; however, the association of this alteration with an increased risk of LZTR1-related schwannomatosis (SWN) is unknown.
CeGaT Center for Human Genetics Tuebingen RCV000658480 SCV004011380 pathogenic not provided 2023-06-01 criteria provided, single submitter clinical testing LZTR1: PS2, PM2, PP1:Moderate, PS4:Moderate, PP3, PS3:Supporting
PreventionGenetics, part of Exact Sciences RCV004530087 SCV004714432 pathogenic LZTR1-related disorder 2023-11-13 criteria provided, single submitter clinical testing The LZTR1 c.850C>T variant is predicted to result in the amino acid substitution p.Arg284Cys. This variant has been reported to be de novo and to segregate with disease in multiple individuals with Noonan syndrome (Yamamoto et al. 2015. PubMed ID: 25795793; Motta et al. 2018. PubMed ID: 30481304; Jacquinet et al. 2020. PubMed ID: 30664951). This variant has also been reported as de novo in multiple individuals with autism spectrum disorders (Table S1, Takata et al. 2018. PubMed ID: 29346770; Table S20, Fu et al. 2022. PubMed ID: 35982160; Table S1, Zhou et al. 2022. PubMed ID: 35982159). Additionally, this variant has been reported as de novo in an individual with schwannomatosis (Paganini et al. 2015. PubMed ID: 25335493). Functional studies found this variant results in enhanced EGF-dependent ERK1/2 phosphorylation (Motta et al. 2018. PubMed ID: 30481304). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic.
OMIM RCV000191028 SCV000246008 pathogenic Noonan syndrome 10 2015-06-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.